Addressing Cancer Care Disparities in Europe: Insights from the 2025 Comparator Report

By João L. Carapinha

March 27, 2025

The “Comparator Report on Cancer in Europe 2025” analyzes the landscape of cancer care across Europe. It highlights cancer care disparities persisting in different European regions and cancer types. While advances in treatment exist, many patients still struggle to access timely and effective care. Molecular diagnostics are also key for precision oncology but vary in access. Lower-income regions lack complex assays, worsening disparities in care quality.

Cancer is the world’s second-leading cause of death, with nearly 10 million deaths in 2020. The OECD’s “Health at a Glance 2023” stresses the need for better prevention and care strategies in Europe.

Rising Incidence and Reimbursement Speed

Cancer incidence in Europe rose by 58% from 1995 to 2022, reaching 3.2 million new cases yearly. Mortality rates have stabilized at 1.3-1.4 million deaths since 2008, reflecting complex factors influencing outcomes. Direct cancer treatment costs doubled from €62 billion in 1995 to €146 billion in 2023. Medicine costs now exceed 40% of total expenses, worsening access for disadvantaged groups.

Wealthier Western European countries quickly reimburse EMA-approved drugs. Meanwhile, Central and Eastern Europe face delays and restricted coverage. These cancer care disparities demand equitable policies to bridge gaps.

Implications for Health Economics and Market Access

Health Economics and Outcomes Research (HEOR) can improve cancer care access. It provides evidence to optimize resource allocation and cost-effectiveness. Frameworks like the ISPOR Value Flower could integrate societal impacts into HTA. Performance-based MEAs and multi-speed HTA processes may prioritize promising drugs while monitoring uncertain ones.

More public funding is needed for treatment optimization studies and data infrastructure. Evolving HTA methodologies should adopt a societal perspective to ensure fair access to innovative treatments.

These findings highlight the urgency of addressing cancer care disparities. HEOR can enhance equity and efficiency in healthcare. For deeper insights, explore the full report.

 

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.